Import and Trade Surplus Expansion in China's E-Cigarette Industry

Jul.04.2022
Import and Trade Surplus Expansion in China's E-Cigarette Industry
China's electronic cigarette industry has a thriving import-export market with a strong supply chain and growing trade surplus.

The central focus of this article is the amount of imported electronic cigarettes in the Chinese industry and the price levels of these imported products.

 

The trade surplus continues to widen.

 

After years of rapid development, the e-cigarette industry in China has created a comprehensive supply chain centered around Guangdong province. With the increasingly global popularity of vaping, China's e-cigarette exports have surged, resulting in a growing trade surplus. In 2021, China's e-cigarette industry recorded a trade surplus of $15.692 billion.

 

From January to April 2022, China's electronic cigarette trade surplus was $4.374 billion.

 

Imports surpass $5.7 billion in 2021.

 

The domestic electronic cigarette industry in China has a highly integrated supply chain, resulting in a surplus of electronic cigarette production compared to market demand. Therefore, overall, the level of import trade in the electronic cigarette industry in China is not high. In 2021, the total import value of the electronic cigarette industry in China was 5.702 billion yuan, an increase of 8.96% compared to 2020.

 

In the first four months of 2022, China's electronic cigarette industry has imported products worth a total of $1.794 billion.

 

The import price of atomization equipment is the highest.

 

Electronic cigarettes account for 73% of imports.

 

Japan is the largest source of imported electronic cigarettes in our country.

 

Looking at the import sources of the electronic cigarette industry in China, Japan is the largest importer of electronic cigarettes to China. In 2021, China imported electronic cigarette-related products from Japan worth over 6.256 billion yuan. Additionally, China imported electronic cigarette-related products from the United States, Taiwan, and Germany, each exceeding 3.5 billion yuan.

 

This article contains excerpts or reprints from third-party sources, which are copyrighted to the original media and author. If there is any infringement, please contact us to delete it. Any unit or individual who needs to reprint should contact the author, and should not reprint directly.

 

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
Philip Morris International said it presented scientific evidence to the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee to support its ZYN nicotine pouches seeking a modified risk tobacco product designation, which would allow the company to communicate to adult smokers that switching completely to ZYN could reduce the risk of multiple smoking-related diseases.
Jan.26 by 2FIRSTS.ai
Juul, NJOY and Altria Clash Over Use of UCSF Public Documents in U.S. Patent Litigation
Juul, NJOY and Altria Clash Over Use of UCSF Public Documents in U.S. Patent Litigation
Juul Labs has asked a U.S. federal court to prevent NJOY and Altria from using documents stored in a public UCSF database in an ongoing patent lawsuit, arguing they are protected by attorney–client privilege. The defendants say the files have long been public and may contain evidence relevant to Juul’s patent conduct.
Dec.29 by 2FIRSTS.ai
2Firsts Interview | Prague Move Puts Eastern Europe in Focus for Nicotine Industry Event EVO NXT
2Firsts Interview | Prague Move Puts Eastern Europe in Focus for Nicotine Industry Event EVO NXT
EVO NXT will move to Prague in April 2026. As an event’s official media partner for four consecutive years, 2Firsts recently interviewed the organisers, who said the relocation reflects strong growth in Eastern European markets for alternative nicotine products. They described EVO NXT as not a traditional trade fair but a business festival shaped by rapid changes in regulation, markets and technological innovation across the global nicotine industry.
Feb.03
Imperial Brands’ blu adds “Creamy Tobacco” flavour, rolling out across device kits and pod products
Imperial Brands’ blu adds “Creamy Tobacco” flavour, rolling out across device kits and pod products
Imperial Brands’ vaping brand blu has outlined its flavour roadmap for 2026 on its official website, adding a new “Creamy Tobacco” flavour that has been rolled out across the rechargeable blu bar kit and its compatible blu kit pods. The brand describes the flavour as offering a more velvety tobacco taste.
Dec.19
UK, Jersey and Guernsey to Ban Disposable Vapes From Jan. 31 as Island Sell-Through Window Closes
UK, Jersey and Guernsey to Ban Disposable Vapes From Jan. 31 as Island Sell-Through Window Closes
Jersey and Guernsey will enforce a full ban on disposable vapes from Saturday, 31 January 2026, making it illegal for shops to sell them after close of business. Online purchases shipped into the islands will also be targeted, with Guernsey’s Director of Public Health Dr Nicola Brink saying Customs will conduct checks and can seize imported disposables. Refillable vapes are not covered by the ban.
Jan.29 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11